Investigational drug · Phase 2
XNW27011
Also called: ASP546C
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "XNW27011"
First trial start
2023
Jul 27, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "XNW27011", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
- Pancreatic Adenocarcinoma
- Pancreatic Adenocarcinoma Metastatic
- Lung Cancer (NSCLC)
- Ovarian Cancer
- Colorectal Cancer Metastatic
- Biliary Tract Cancer
- Gastric Carcinoma
- Gastroesophageal Junction Adenocarcinoma
Approved drugs for the same conditions: Non-small cell lung cancer · Colorectal cancer · Ovarian cancer · Pancreatic cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "XNW27011" as an intervention, largest first.
- XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.Active, not recruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT06792435 · 240 participants (planned) · Start Jul 27, 2023 · Primary completion Dec 30, 2026
Drug: XNW27011; XNW27011 · For: Pancreatic Adenocarcinoma Metastatic; Lung Cancer (NSCLC); Ovarian Cancer and 4 more
Sites: Jinan, China
- A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid TumorsPivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07488676 · 150 participants (planned) · Start May 4, 2026 · Primary completion Jul 31, 2029
Drug: ASP546C · For: Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma; Pancreatic Adenocarcinoma
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 35 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Astellas.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.